Patents by Inventor Lars Daniel Engstrom

Lars Daniel Engstrom has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapies
    Patent number: 12377101
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: August 5, 2025
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: James Gail Christensen, Lars Daniel Engstrom, Peter Olson, Ruth Wei Aranda
  • Combination therapies
    Patent number: 12336995
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: June 24, 2025
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: James Gail Christensen, Lars Daniel Engstrom, Ruth Wei Aranda, Jill Hallin, Peter Olson
  • COMBINATION THERAPIES
    Publication number: 20250177399
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a MEK inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: January 28, 2022
    Publication date: June 5, 2025
    Inventors: James Gail CHRISTENSEN, Lars Daniel ENGSTROM, Jacob HALING, Jill HALLIN
  • COMBINATION THERAPIES
    Publication number: 20250108055
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: October 3, 2024
    Publication date: April 3, 2025
    Inventors: Ruth Wei Aranda, James Gail Christensen, Lars Daniel Engstrom, Jill Hallin, Peter Olson
  • Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer
    Publication number: 20250073241
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.
    Type: Application
    Filed: November 19, 2024
    Publication date: March 6, 2025
    Applicant: MIRATI THERAPEUTICS, INC.
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • Combination therapies
    Patent number: 12208099
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: January 28, 2025
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Ruth Wei Aranda, James Gail Christensen, Lars Daniel Engstrom, Jill Hallin, Peter Olson
  • Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer
    Publication number: 20240423987
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
    Type: Application
    Filed: September 5, 2024
    Publication date: December 26, 2024
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • Combination therapies using PRMT5 inhibitors for the treatment of cancer
    Patent number: 12171765
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: December 24, 2024
    Assignee: MIRATI THERAPEUTICS, INC.
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • COMBINATION THERAPIES USING PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20240398795
    Abstract: Disclosed herein are methods of treating cancer. More specifically, this disclosure provides methods for treating cancer in a subject using compounds that are inhibitors of PRMT5, particularly in combination with a taxane.
    Type: Application
    Filed: October 6, 2022
    Publication date: December 5, 2024
    Inventors: Peter OLSON, Lars Daniel ENGSTROM, James Gail CHRISTENSEN
  • Combination therapies using PRMT5 inhibitors for the treatment of cancer
    Patent number: 12128048
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: October 29, 2024
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer
    Publication number: 20220331323
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with CDK4/6 inhibitors.
    Type: Application
    Filed: April 5, 2022
    Publication date: October 20, 2022
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • Combination Therapies Using PRMT5 Inhibitors for the Treatment of Cancer
    Publication number: 20220331324
    Abstract: This disclosure relates to methods of treating cancer. This disclosure further relates to treating cancer in a subject with compounds that are inhibitors of PRMT5, particularly in combination with KRASG12C inhibitors.
    Type: Application
    Filed: April 5, 2022
    Publication date: October 20, 2022
    Inventors: Lars Daniel Engstrom, Peter Olson, James Gail Christensen
  • COMBINATION THERAPIES
    Publication number: 20220096482
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a CDK 4/6 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: September 9, 2019
    Publication date: March 31, 2022
    Inventors: James Gail Christensen, Ruth Wei Aranda, Lars Daniel Engstrom, Jill Hallin, Peter Olson
  • COMBINATION THERAPIES
    Publication number: 20220079947
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a SHP-2 inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: December 5, 2019
    Publication date: March 17, 2022
    Inventors: James Gail Christensen, Lars Daniel Engstrom, Peter Olson, Ruth Wei Aranda
  • COMBINATION THERAPIES
    Publication number: 20220054492
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Raf family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: September 10, 2019
    Publication date: February 24, 2022
    Inventors: Ruth Wei Aranda, James Gail Christensen, Lars Daniel Engstrom, Jill Hallin, Peter Olson
  • COMBINATION THERAPIES
    Publication number: 20220054491
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a pan ErbB family inhibitor and a KRAS G12C inhibitor of Formula (I), Formula (I-A) or Formula (I-B), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: September 9, 2019
    Publication date: February 24, 2022
    Inventors: James Gail Christensen, Lars Daniel Engstrom, Ruth Wei Aranda, Jill Hallin, Peter Olson
  • COMBINATION THERAPIES
    Publication number: 20220040181
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a Src-family kinase inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: September 9, 2019
    Publication date: February 10, 2022
    Inventors: Lars Daniel Engstrom, Ruth Wei Aranda, Peter Olson, James Gail Christensen
  • COMBINATION THERAPIES
    Publication number: 20220040182
    Abstract: The present invention relates to combination therapies for treating KRas G12C cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of a mTOR inhibitor and a KRAS G12C inhibitor of Formula (I), Formula I-A or Formula I-B, pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitors, kits comprising the compositions and methods of use therefor.
    Type: Application
    Filed: September 10, 2019
    Publication date: February 10, 2022
    Inventors: Peter Olson, Ruth Wei Aranda, James Gail Christensen, Lars Daniel Engstrom, Jill Hallin